About Nuclein
Nuclein is a company based in Austin (United States) founded in 2017.. Nuclein has raised $18.97 million across 5 funding rounds from investors including Trinity Investors. Nuclein offers products and services including DASH Rapid PCR System and DASH SARS-CoV-2 & Flu A/B Test. Nuclein operates in a competitive market with competitors including CellScope, Orphidia, Mel-Mont Medical, ParaSonic and PreDiagnose, among others.
- Headquarter Austin, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nuclein, Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$18.97 M (USD)
in 5 rounds
-
Latest Funding Round
$9.78 M (USD), Debt – Conventional
Jul 01, 2025
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nuclein
Nuclein offers a comprehensive portfolio of products and services, including DASH Rapid PCR System and DASH SARS-CoV-2 & Flu A/B Test. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Delivers lab-quality PCR results in 15 minutes for point-of-care use.
Enables detection of SARS-CoV-2 and influenza viruses via PCR.
Unlock access to complete
Funding Insights of Nuclein
Nuclein has successfully raised a total of $18.97M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $9.78 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Debt – Conventional — $9.8M
-
First Round
First Round
(24 Mar 2021)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Debt – Conventional - Nuclein | Valuation |
investors |
|
| Jan, 2025 | Amount | Series B - Nuclein | Valuation |
investors |
|
| Dec, 2023 | Amount | Debt – Conventional - Nuclein | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nuclein
Nuclein has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Trinity Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nuclein
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nuclein
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nuclein Comparisons
Competitors of Nuclein
Nuclein operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CellScope, Orphidia, Mel-Mont Medical, ParaSonic and PreDiagnose, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
In-ear visibility is enabled by smartphone-attached otoscope for at-home diagnosis.
|
|
| domain | founded_year | HQ Location |
Handheld device for point-of-care chronic disease diagnostics is developed.
|
|
| domain | founded_year | HQ Location |
Molecular screening devices for early infectious disease detection are developed.
|
|
| domain | founded_year | HQ Location |
Offers a home-use device for effectively eliminating lice and other parasites.
|
|
| domain | founded_year | HQ Location |
Point-of-care devices for early bacterial infection detection are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nuclein
Frequently Asked Questions about Nuclein
When was Nuclein founded?
Nuclein was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Where is Nuclein located?
Nuclein is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Is Nuclein a funded company?
Nuclein is a funded company, having raised a total of $18.97M across 5 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $8.79M, raised on Mar 24, 2021.
What does Nuclein do?
Nuclein was founded in 2017 in Austin, United States, and operates in the medical diagnostics sector. A handheld PCR device named NUCLEIN is developed, utilizing standard real-time PCR technology. No technical expertise is required for operation, and the battery-powered unit delivers results within one hour. Applications include diagnosis of COVID-19 and other infectious diseases in field settings.
Who are the top competitors of Nuclein?
Nuclein's top competitors include CellScope, Mel-Mont Medical and Orphidia.
What products or services does Nuclein offer?
Nuclein offers DASH Rapid PCR System and DASH SARS-CoV-2 & Flu A/B Test.
Who are Nuclein's investors?
Nuclein has 1 investor. Key investors include Trinity Investors.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.